trial · primary record
PEP-CMV vaccine
Diffuse Midline Glioma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 68 |
| Primary completion | 2051-06-30 |
| Primary endpoint | Proportion of patients with unacceptable toxicity |
| Registry ID | NCT06639607 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:41.758Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06639607
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.